Risperidone-induced neuroleptic malignant syndrome

Annals of Pharmacotherapy

Volumn 30, Issue 7-8, 1996, Pages 775-778

  Sharma, Roopali ^a,b,c   Trappler, Brian ^b   Ng, Yiu Kee ^b   Leeman, Cavin P ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE; HALOPERIDOL; LITHIUM CARBONATE; RISPERIDONE; VALPROIC ACID;

ADOLESCENT; ARTICLE; AUTONOMIC DYSFUNCTION; CASE REPORT; FEVER; HUMAN; MALE; MENTAL HEALTH; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0030054382     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000713     Document Type: Article

References (21)

1. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. Un neuroleptique majeur nonphenothiazine et non-reserpinique, l'haloperidol, dans le traitement des psychoses. Ann Med Psychol 1960;118:145-52.
2. Caroff SN, Mann SC. A brief review of the 250 cases of NMS reported in the literature from 1980-7. Psychopharmacol Bull 1988;24:25-9.
3. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986;143:1227-33.
4. Freidman JH, Davis R, Wagner R. Brief report - neuroleptic malignant syndrome. The result of a 6 month prospective study of incidence in a state psychiatric hospital. Clin Neuropharmacol 1988;52:578-86.
5. Crurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992;53:56-62.
6. Ebadi M, Pfeiffer RF, Murrin LC. Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol 1992;21:367-86.
7. Legras A, Hurel D, Dabrowski G, Grenet D, Gravrleau P, Loirat P. Protracted neuroleptic malignant syndrome complicating long-acting neuroleptic administration. Am J Med 1988;86:875-8.
8. Koehler PJ, Mirandolle JF. Neuroleptic malignant-like syndrome and lithium. Lancet 1988;22:1499-500.
9. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994;344:1228-9.
10. Lee H, Ryan J, Mullett G, Lawlor BA. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Hum Psychopharmacol 1994;9:303-5.
11. Raitasuo V, Vataja R, Elomaa E. Risperidone-induced neuroleptic malignant syndrome in young patient. Lancet 1994;344:1705.
12. Tomsic J, Chatt PL, Chandarana P. Neuroleptic malignant syndrome caused by risperidone (abstract). Poster at the 25th Annual Professional Practice Conference of the Canadian Society of Hospital Pharmacists, 1994.
13. Najara JE, Enikeev I. Risperidone and neuroleptic malignant syndrome, a case report. J Clin Psych 1995;56:534-5.
14. Singer S, Richards C, Boland RJ. Two cases of risperidone-induced neuroleptic malignant syndrome (letter). Am J Psychiatry 1995;152:1234.
15. Murray S, Haller E. Risperidone and NMS (letter)? Psychiatr Serv 1995; 46:951.
16. Dave M. Two cases of risperidone-induced neuroleptic malignant syndrome (letter). Am J Psychiatry 1995;152:1233-4.
17. Levin G, Lazowick A, Powell H. J Clin Psychopharmacol (in press).
18. Chouinard G, Jones B, Remington G. A Canadian multi-center placebo controlled study of fixed doses of risperidone and haloperidol with treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40.
19. Joshi PT, Capozzoli JA, Coyle JT. The Johns Hopkins Depression Scale. Narrative data and validation in child psychiatry patient. J Am Acad Child Adolesc Psychiatry 1990;29:283-8.
20. 2 receptor blockade in vivo with the novel antipsychotics risperidone, remoxipride: a 1233I-IBMZ single photon emission tomography (SPET) study. Psychopharmacology 1995;22:42-6.
21. Cozza SJ, Edison DL. Risperidone in adolescents. J Am Acad Child Adolesc Psychiatry 1994;33:8.